NASDAQ:NAMS NewAmsterdam Pharma (NAMS) Stock Price, News & Analysis $25.31 +2.35 (+10.24%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$25.14 -0.16 (-0.65%) As of 08/8/2025 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About NewAmsterdam Pharma Stock (NASDAQ:NAMS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NewAmsterdam Pharma alerts:Sign Up Key Stats Today's Range$23.23▼$25.8550-Day Range$17.96▼$25.3152-Week Range$14.06▼$27.29Volume1.84 million shsAverage Volume740,259 shsMarket Capitalization$2.84 billionP/E RatioN/ADividend YieldN/APrice Target$41.20Consensus RatingModerate Buy Company Overview NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands. Read More NewAmsterdam Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreNAMS MarketRank™: NewAmsterdam Pharma scored higher than 72% of companies evaluated by MarketBeat, and ranked 272nd out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingNewAmsterdam Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNewAmsterdam Pharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about NewAmsterdam Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for NewAmsterdam Pharma are expected to decrease in the coming year, from ($1.75) to ($1.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NewAmsterdam Pharma is -15.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NewAmsterdam Pharma is -15.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNewAmsterdam Pharma has a P/B Ratio of 3.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.06% of the float of NewAmsterdam Pharma has been sold short.Short Interest Ratio / Days to CoverNewAmsterdam Pharma has a short interest ratio ("days to cover") of 8.4.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNewAmsterdam Pharma does not currently pay a dividend.Dividend GrowthNewAmsterdam Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.06% of the float of NewAmsterdam Pharma has been sold short.Short Interest Ratio / Days to CoverNewAmsterdam Pharma has a short interest ratio ("days to cover") of 8.4.Change versus previous month News and Social Media3.2 / 5News Sentiment0.68 News SentimentNewAmsterdam Pharma has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for NewAmsterdam Pharma this week, compared to 6 articles on an average week.Search Interest1 people have searched for NAMS on MarketBeat in the last 30 days. Company Ownership5.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, NewAmsterdam Pharma insiders have sold 1,599.84% more of their company's stock than they have bought. Specifically, they have bought $236,839.00 in company stock and sold $4,025,887.00 in company stock.Percentage Held by Insiders20.84% of the stock of NewAmsterdam Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.89% of the stock of NewAmsterdam Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NewAmsterdam Pharma's insider trading history. Receive NAMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NewAmsterdam Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address NAMS Stock News HeadlinesDouglas F. Kling Sells 47,569 Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) StockJuly 18, 2025 | insidertrades.comScotiabank Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)1 hour ago | theglobeandmail.com#1 Pre-IPO Opportunity For 2025 [Take Action Now!]James Altucher has scored 37X and even 60X returns on past pre-IPO deals. But now he says a much bigger opportunity is taking shape—one tied to what could be the largest IPO in history: Elon Musk’s Starlink. With the IPO rumored to launch as soon as this year, James has uncovered a backdoor method to potentially profit before it goes public—starting with as little as $50. | Paradigm Press (Ad)NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Up 10.1% on Analyst Upgrade3 hours ago | americanbankingnews.comAnalysts Are Upgrading NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) After Its Latest ResultsAugust 9 at 5:42 PM | finance.yahoo.comWhat 5 Analyst Ratings Have To Say About NewAmsterdam Pharma CoAugust 8 at 9:47 AM | benzinga.comNewAmsterdam Pharma Clears Key Benchmark, Hitting 80-Plus RS RatingAugust 7 at 1:24 PM | msn.comNewAmsterdam Pharma Second Quarter 2025 Earnings: US$0.15 loss per share (vs US$0.41 loss in 2Q 2024)August 7 at 8:23 AM | finance.yahoo.comSee More Headlines NAMS Stock Analysis - Frequently Asked Questions How have NAMS shares performed this year? NewAmsterdam Pharma's stock was trading at $25.70 at the start of the year. Since then, NAMS shares have decreased by 1.5% and is now trading at $25.31. How were NewAmsterdam Pharma's earnings last quarter? NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) released its quarterly earnings data on Wednesday, August, 6th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.37. The firm earned $19.15 million during the quarter, compared to analysts' expectations of $1.44 million. NewAmsterdam Pharma had a negative net margin of 259.07% and a negative trailing twelve-month return on equity of 27.27%. Who are NewAmsterdam Pharma's major shareholders? NewAmsterdam Pharma's top institutional investors include Jennison Associates LLC (2.62%), TimesSquare Capital Management LLC (0.78%), Aberdeen Group plc (0.65%) and Bank of New York Mellon Corp (0.31%). Insiders that own company stock include Nap BV Forgrowth, James N Topper, Michael H Davidson, Douglas F Kling, Louis G Lange, Louise Frederika Kooij, Juliette Berangere Audet and Johannes Jacob Piete Kastelein. View institutional ownership trends. How do I buy shares of NewAmsterdam Pharma? Shares of NAMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NewAmsterdam Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that NewAmsterdam Pharma investors own include Nextera Energy Partners (NEP), Enterprise Products Partners (EPD), Blue Owl Capital (OBDC), Pimco Corporate & Income Opportunity Fund (PTY), PayPal (PYPL) and Ventyx Biosciences (VTYX). Company Calendar Last Earnings8/06/2025Today8/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NAMS CIK1936258 Webwww.newamsterdampharma.com Phone352062971FaxN/AEmployees4Year FoundedN/APrice Target and Rating Average Price Target for NewAmsterdam Pharma$41.20 High Price Target$52.00 Low Price Target$27.00 Potential Upside/Downside+62.8%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$241.60 million Net Margins-259.07% Pretax Margin-258.91% Return on Equity-27.27% Return on Assets-25.00% Debt Debt-to-Equity RatioN/A Current Ratio21.08 Quick Ratio19.98 Sales & Book Value Annual Sales$45.56 million Price / Sales62.37 Cash FlowN/A Price / Cash FlowN/A Book Value$6.93 per share Price / Book3.65Miscellaneous Outstanding Shares112,270,000Free Float88,874,000Market Cap$2.84 billion OptionableOptionable Beta-0.02 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:NAMS) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Company N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.